Clerio Vision

Executive Summary

Clerio Vision is a development-stage medical device company pioneering LIRIC®, a non-invasive laser technology that alters the refractive index of materials without cutting or removing tissue. Founded in 2018 and based on Nobel Prize-winning research, the company targets four major ophthalmic segments: contact lenses for presbyopia, myopia control, intraocular lens adjustment, and laser vision correction. By modifying the refractive properties of hydrogel lenses or corneal tissue, LIRIC offers a transformative approach to vision correction with potential advantages in safety, precision, and reversibility. Currently, Clerio is advancing its preclinical and early clinical development, with a focus on obtaining regulatory approval for its first indication—likely contact lens modification for presbyopia, addressing a large and underserved patient population. The technology has broad applicability, and successful validation could position Clerio as a disruptor in the ophthalmic device market, which is dominated by surgical and ablative techniques.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical data for LIRIC contact lens platform60% success
• Q3 2026Regulatory submission for presbyopia indication (e.g., FDA 510(k) or IDE)40% success
• Q4 2026Strategic partnership or licensing deal with major ophthalmic company30% success